Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD

NCT02348359 is registered in ClinicalTrials.gov with Tyrogenex as lead sponsor.

NCT NCT02348359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02348359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD
Lead sponsor
Tyrogenex
Phase
Phase 2
Overall status
Terminated
Start date
March 16, 2015
Completion date
January 12, 2018
Enrollment
157 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (amd), amd, exudative age-related macular degeneration, eye diseases, macular degeneration, macular degeneration, age-related, 10, retinal degeneration, retinal diseases